NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), announced today the presentation of ZIO-101 (darinaparsin) Phase I data at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The poster presented in the Developmental Therapeutics poster discussion session entitled, “Organic arsenic in advanced cancers: Preliminary Phase 1 results of ZIO-101(S-dimethylarsino-glutathione)” was presented by Luis H. Camacho, M.D., M.P.H., University of Texas M. D. Anderson Cancer Center and principal investigator. Darinaparsin is a novel organic arsenic with a multifaceted mechanism of action with preclinical activity previously demonstrated in multiple in vitro and animal models.
